SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is experiencing intense volatility and social media attention as investors speculate on a major buyout and an imminent short squeeze following a significant increase in short interest and a high-stakes clinical trial readout. The community is sharply divided, with bulls pointing to institutional positioning and potential acquisition catalysts, while bears focus on trial outcome risks and concerns regarding share dilution.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing intense debate as investors weigh concerns over SaaS valuations and AI disruption against its role as an enterprise orchestration layer, with community sentiment shifting between aggressive accumulation and frustration over recent volatility. Bullish traders are highlighting institutional insider buying and strategic partnerships as catalysts for a potential reversal, while bearish participants question the sustainability of the company's growth in an era of rapid AI development.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is seeing heightened interest as the community speculates on potential price breakouts, frequently comparing its recent performance to previous volatility. Investors are actively discussing the impact of exchange delistings, thin liquidity, and the recurring debate over whether current volume represents a sustainable rally or another pump-and-dump cycle.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on its potential inclusion in the Russell 1000 index, driving significant volume and heightened options activity. The community remains deeply divided between those betting on an imminent short squeeze and others warning that index-related optimism may be a temporary distraction from the company's long-term clinical and regulatory milestones.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors monitor the company's production scaling for its optical engines and upcoming Annual General Meeting, which has become a focal point for updates on customer adoption and potential strategic partnerships. While some community members remain focused on the long-term potential of the company's photonics platform to solve industry bottlenecks, others are expressing frustration over recent stock volatility and the lack of immediate, high-impact news.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

LABU is experiencing a surge in community interest driven by a strong sector rotation into biotech, with many investors closely tracking technical breakouts and leveraging the S&P Biotech index's recent upward momentum. Market participants are actively discussing the impact of AI-driven drug discovery, M&A speculation, and shifting macro expectations for interest rates on the sector's long-term volatility and growth potential.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is currently volatile as traders react to conflicting weekend headlines regarding U.S.-Iran relations, with markets swinging on reports of de-escalation versus ongoing tensions. While bears cite macro concerns and geopolitical risks, the community remains deeply divided, with many actively debating whether the weekend's news represents genuine diplomatic progress or calculated market manipulation.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as shareholders express frustration over ongoing stock underperformance and the recent departure of its CFO, while active community debate focuses on the company's need for a potential acquisition of oncology-focused assets to revitalize its pipeline. Investors are closely monitoring the healthcare sector for signs of a rotation into value-oriented stocks, contrasting Pfizer's stagnant price action with the aggressive growth seen in peers like Eli Lilly.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is trending as investors weigh recent partnership news against a volatile technical breakout, with the community actively debating whether the stock's significant long-term potential in AI-driven drug discovery justifies holding through current price swings. While some bulls point to upcoming clinical data and institutional accumulation as catalysts for a major re-rating, bears continue to emphasize historical underperformance and ongoing selling pressure.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The biotech sector is surging as a wave of M&A activity and positive clinical trial readouts drive a sector-wide rotation, with the XBI ETF drawing significant institutional interest. Market participants are closely watching the XBI as a barometer for broader sector strength, while retail discussions focus on identifying potential buyout targets and capitalizing on renewed momentum in immuno-oncology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ENVX 

Great post on X

https://x.com/vaelis_x/status/2070508359204127029?s=46&amp;t=BbI0iONe1_D-dDauSrNOVQ

GTbuzzbait

Monkeykungfu

Samson

Antonio Arias

Eaton

Big Perm

CarmineJr

Anastasios Pesirides

Spaker

Stephen

Keith

The battery inside your next AI smartphone may end up being just as important as the AI chip itself.The company is $ENVX.Enovix isn't trying to build another lithium-ion battery. It's attempting to solve one of the biggest physical constraints facing edge AI: how do you fit... pic.twitter.com/fKufjw7Odr

X (Formerly Twitter)

Vaelis on X (formerly Twitter): "The battery inside your next AI smartphone may end up being just as important as the AI chip itself.The company is $ENVX.Enovix isn't trying to build another lithium-ion battery. It's attempting to solve one of the bigg...

StockTwits for iOS

Enovix Corp

Steve Crawford

@Stingraystev  show me the money = PO ………

David

@Stingraystev the pivot leaning away from cel phones is not encouraging to me. Raj went all in on cel phones too early and now he’s changing directions. That’s where the real profit would come from if ENVX ever gets pass manufacturing. What’s your thoughts on competition catching up? 

That’s my next biggest concern.  They are 3 years behind and big companies like TDK aren’t just waiting around and they have loads of cash to throw at this.

 the pivot leaning away from cel phones is not encouraging to me. Raj went all in on cel phones too early and now he’s changing directions. That’s where the real profit would come from if ENVX ever gets pass manufacturing. What’s your thoughts on competition catching up? 

That’s my next biggest concern.  They are 3 years behind and big companies like TDK aren’t just waiting around and they have loads of cash to throw at this.

Juicer123

@Juicer123 I see cellphones more as a timing issue than abandoning the market. It makes sense to prove the technology in premium, lower volume markets before taking on the huge volume and pricing demands of smartphones. My bigger concern is competition. Companies like TDK, Murata, and Samsung SDI have deep pockets, world class engineering teams, and aren’t standing still. While Enovix may have a technological lead today, those advantages don’t last forever if execution falls behind. Every delay in scaling manufacturing gives competitors more time to narrow the gap. That’s why I believe manufacturing execution, not the technology itself is the biggest risk. If Enovix can scale production and secure meaningful commercial wins over the next few years, it has a real chance to establish itself before competitors catch up. If not, the competitive threat becomes much more significant. I think they will make it imho.

 I see cellphones more as a timing issue than abandoning the market. It makes sense to prove the technology in premium, lower volume markets before taking on the huge volume and pricing demands of smartphones. My bigger concern is competition. Companies like TDK, Murata, and Samsung SDI have deep pockets, world class engineering teams, and aren’t standing still. While Enovix may have a technological lead today, those advantages don’t last forever if execution falls behind. Every delay in scaling manufacturing gives competitors more time to narrow the gap. That’s why I believe manufacturing execution, not the technology itself is the biggest risk. If Enovix can scale production and secure meaningful commercial wins over the next few years, it has a real chance to establish itself before competitors catch up. If not, the competitive threat becomes much more significant. I think they will make it imho.

@Stingraystev they have so much to prove and the longer it takes the less chance they have to succeed. They just need to give investors something. Good news or even a minimal PO. They have been in idle mode for a year now.

 they have so much to prove and the longer it takes the less chance they have to succeed. They just need to give investors something. Good news or even a minimal PO. They have been in idle mode for a year now.